Wigginton to lead R&D at Bright Peak

Immunotherapy company Bright Peak Therapeutics Inc. named Jon Wigginton as president of R&D. Most recently, Wigginton was senior adviser and chairman of the scientific advisory board of Cullinan Oncology Inc. (NASDAQ:CGEM), having previously been that company’s CMO. Prior to that, he was CMO at MacroGenics Inc. (NASDAQ:MGNX).

Antibody company CDR-Life Inc. hired Swethajit Biswas as CMO. Biswas was a development leader at Adaptimmune Therapeutics plc and clinical director in oncology drug development at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). CDR is harnessing the high affinity of antibody fragments to develop a new class of bispecifics that can target intracellular cancer antigens...